Get started
Work

Precision virotherapy for IDH-mutant astrocytoma

Year: 2026
Type: article
Abstract: Despite decades of investigation, high-grade diffuse gliomas remain among the most therapeutically challenging malignancies. While molecular classification has transformed our understanding of glioma biology, relatively few genomic alterations have been translated into predictive biomarkers that guide therapeutic selection. The discovery of recurrent mutations in isocitrate dehydrogenase 1 (IDH1; codon 132) or 2 (IDH2; codon 172) genes fundamentally redefined diffuse glioma classification, revealing profound metabolic, epigenetic, and immunological differences that may influence tumor progression.
DOI: 10.1016/j.omton.2026.201326
Institutions: Beth Israel Deaconess Medical Center, Harvard University, Brown University, Broad Institute, Koch Institute for Integrative Cancer Research At MIT, Massachusetts Institute of Technology, Mass General Brigham
Language: English
Subfield: Genetics
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,900
Awards: Understanding and Overcoming T cell Immunosuppression in Glioblastoma, G8003270942, G9000080925, G9000107236, G9000345484, Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas, Defining the role of cytomegalovirus in glioblastoma therapies
OpenAlex ID: W7204547444
FWCI:
Cites: 10
Cited by:
Related to: